A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506033-29-00

Acronym

61186372NSC3001

Enrollment

Registered

2024-02-21

Start date

2020-10-09

Completion date

Unknown

Last updated

2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Brief summary

Progression-Free Survival (PFS) (using RECIST v1.1 guidelines), as assessed by blinded independent central review (BICR)

Interventions

DRUGPemetrexed Seacross 500 mg powder for concentrate for solution for infusion

DRUGJNJ-61186372

DRUGPEMETREXED

DRUGCarboplatin 10 mg/ml Intravenous Infusion

DRUGCARBOPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival (PFS) (using RECIST v1.1 guidelines), as assessed by blinded independent central review (BICR)	—

Countries

Belgium, France, Germany, Hungary, Italy, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026